Or Refractory Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Or Refractory Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease [Phase 1]
Phase 1 clinical trial evaluating autologous CAR-T cells targeting Kappa Myeloma Antigen (KMA) in patients with relapsed or refractory multi…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies [Phase 1]
Phase 1 safety study SG301 in relapsed or refractory multiple myeloma and other hematologic malignancies is currently active but not recruit…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) [Phase 1]
A Phase 1 study assessing safety, pharmacokinetics, and activity of the combination of cevostamab and elranatamab in relapsed or refractory …
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) [Phase 3]
This document provides an update on a phase 3 clinical trial (SUCCESSOR-2) evaluating mezigdomide in combination with carfilzomib and dexame…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma [Phase 1]
A Phase 1 study evaluating the safety and efficacy of SAR446523 given by subcutaneous injection in adults with relapsed or refractory multip…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM [Phase 1]
Phase 1 clinical trial evaluating a BCMA/CD3 bispecific antibody as bridging therapy before CAR-T cell infusion in relapsed or refractory mu…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating YKST02 in participants with relapsed or refractory multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM [Phase 1]
This document summarizes a Phase 1 clinical trial update evaluating a DC/MM fusion vaccine in combination with BCMA-targeted CAR-T therapy f…
-
CLINICAL_TRIALS research · 2025-12-31Clinical Trial Update: A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on F182112 for relapsed or refractory multiple myeloma; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating adverse events and changes in disease activity of intravenously infused Etentamig (ABBV-383) in combinat…
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
The pre-approval access program for talquetamab in relapsed or refractory multiple myeloma is no longer available.
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration [Phase 1]
A Phase 1 clinical trial update on a dual-target BCMA-GPRC5D CAR-T cell therapy for relapsed or refractory multiple myeloma with extramedull…
-
CLINICAL_TRIALS research · 2025-05-29Clinical Trial Update: Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma [NA]
A clinical trial is evaluating intravenous autologous CD19 CAR-T cells for relapsed or refractory lymphoblastic leukemia and relapsed/refrac…
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL [Phase 1]
First-in-human, single-agent study of SAR442257 in relapsed/refractory multiple myeloma and relapsed/refractory non-Hodgkin lymphoma. The tr…
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy
This is an observational long-term follow-up study related to patients treated with gene-modified T-cell therapy for relapsed or refractory …
-
CLINICAL_TRIALS research · 2025-02-11Clinical Trial Update: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]
Phase 3 trial evaluating ATG-010 in combination with Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in relapsed or refract…